Exact Mass: 491.29479
Exact Mass Matches: 491.29479
Found 123 metabolites which its exact mass value is equals to given mass value 491.29479
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Bardoxolone
C31H41NO4 (491.30354260000007)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C29574 - Nitric Oxide Synthase Inhibitor C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
N-Docosahexaenoyl Tyrosine
C31H41NO4 (491.30354260000007)
N-docosahexaenoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Tyrosine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Bardoxolone
C31H41NO4 (491.30354260000007)
3,9,14,15alpha,16beta,20-Hexahydroxy-A-nor-5beta-cevan-3alpha-carbonsaeure-9-lacton|3,9,14,15alpha,16beta,20-hexahydroxy-A-nor-5beta-cevane-3alpha-carboxylic acid-9-lactone
C27H41NO7 (491.28828760000005)
(2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,5S,7S)-7-hydroxy-7-methyl-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate
C27H41NO7 (491.28828760000005)
Ala Phe Arg Val
Ala Phe Val Arg
Ala Arg Phe Val
Ala Arg Val Phe
Ala Val Phe Arg
Ala Val Arg Phe
Phe Ala Arg Val
Phe Ala Val Arg
Phe Gly Ile Arg
Phe Gly Leu Arg
Phe Gly Arg Ile
Phe Gly Arg Leu
Phe Ile Gly Arg
Phe Ile Arg Gly
Phe Leu Gly Arg
Phe Leu Arg Gly
Phe Arg Ala Val
Phe Arg Gly Ile
Phe Arg Gly Leu
Phe Arg Ile Gly
Phe Arg Leu Gly
Phe Arg Val Ala
Phe Val Ala Arg
Phe Val Arg Ala
Gly Phe Ile Arg
Gly Phe Leu Arg
Gly Phe Arg Ile
Gly Phe Arg Leu
Gly Ile Phe Arg
Gly Ile Arg Phe
Gly Leu Phe Arg
Gly Leu Arg Phe
Gly Arg Phe Ile
Gly Arg Phe Leu
Gly Arg Ile Phe
Gly Arg Leu Phe
Ile Phe Gly Arg
Ile Phe Arg Gly
Ile Gly Phe Arg
Ile Gly Arg Phe
Ile Arg Phe Gly
Ile Arg Gly Phe
Leu Phe Gly Arg
Leu Phe Arg Gly
Leu Gly Phe Arg
Leu Gly Arg Phe
Leu Arg Phe Gly
Leu Arg Gly Phe
Arg Ala Phe Val
Arg Ala Val Phe
Arg Phe Ala Val
Arg Phe Gly Ile
Arg Phe Gly Leu
Arg Phe Ile Gly
Arg Phe Leu Gly
Arg Phe Val Ala
Arg Gly Phe Ile
Arg Gly Phe Leu
Arg Gly Ile Phe
Arg Gly Leu Phe
Arg Ile Phe Gly
Arg Ile Gly Phe
Arg Leu Phe Gly
Arg Leu Gly Phe
Arg Val Ala Phe
Arg Val Phe Ala
Val Ala Phe Arg
Val Ala Arg Phe
Val Phe Ala Arg
Val Phe Arg Ala
Val Arg Ala Phe
Val Arg Phe Ala
(5R,11R,13S,14S,17S)-11-[4-(Dimethylamino)phenyl]-13-methyl-17-(1 -propyn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyc lopenta[a]phenanthrene-3,2-[1,3]dioxolane]-5,17(4H)-diol
C31H41NO4 (491.30354260000007)
(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
C28H37N5O3 (491.28962520000005)
(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
C28H37N5O3 (491.28962520000005)
(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
C28H37N5O3 (491.28962520000005)
(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
C28H37N5O3 (491.28962520000005)
[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] propanoate
lysophosphatidylcholine 16:2
A lysophosphatidylcholine in which the remaining acyl group contains 16 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
NA-Tyr 22:6(4Z,7Z,10Z,13Z,16Z,19Z)
C31H41NO4 (491.30354260000007)
[(3r,3ar,4s,5r,11ar)-5-(acetyloxy)-4-hydroxy-10-methyl-2-oxo-3-(piperidin-1-ylmethyl)-3h,3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-yl]methyl (2r)-2-methylbutanoate
C27H41NO7 (491.28828760000005)
7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
C27H41NO7 (491.28828760000005)
(1r,2r,3r,4r,5r,6r,8s,9r,10s,13r,16s,17s)-4-(acetyloxy)-11-ethyl-16-hydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
C27H41NO7 (491.28828760000005)
14-ethyl-6,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-4-yl acetate
C27H41NO7 (491.28828760000005)
(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-4-(acetyloxy)-11-ethyl-16-hydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
C27H41NO7 (491.28828760000005)
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
C27H41NO7 (491.28828760000005)
(1'r,2s,3s,4's,5r,5'r,7'r,11'r,14'r)-4'-hydroxy-5-(3-hydroxy-2-methylprop-1-en-1-yl)-16'-(2-hydroxyethyl)-3,4',7'-trimethyl-2'-oxa-16'-azaspiro[oxolane-2,10'-tetracyclo[12.3.0.0¹,⁵.0⁷,¹¹]heptadecane]-15',17'-dione
C27H41NO7 (491.28828760000005)
(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-4-(acetyloxy)-11-ethyl-8-hydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-yl acetate
C27H41NO7 (491.28828760000005)
(4e,10e)-8,14-dimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-1(21),2,4,10,18(22),19-hexaene-3,9,13,19,20-pentol
C27H41NO7 (491.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,12r,13s,16s,19s,20r)-14-ethyl-6,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-4-yl acetate
C27H41NO7 (491.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,12s,13s,16r,19r,20r,21s)-14-ethyl-4,6,19-trimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-21-yl acetate
C27H41NO7 (491.28828760000005)
[5-(acetyloxy)-4-hydroxy-10-methyl-2-oxo-3-(piperidin-1-ylmethyl)-3h,3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-yl]methyl 2-methylbutanoate
C27H41NO7 (491.28828760000005)
3-{6-[(2e)-4,6-dimethyloct-2-en-2-yl]-5-methyl-3,6-dihydro-2h-pyran-2-yl}-4-hydroxy-1-methyl-5-(2,3,4,5-tetrahydroxycyclopentyl)pyridin-2-one
C27H41NO7 (491.28828760000005)
4-(acetyloxy)-11-ethyl-8-hydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-yl acetate
C27H41NO7 (491.28828760000005)
(1s,3s,7s,10r,11r,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
C27H41NO7 (491.28828760000005)